Epcoritamab

• CAT Number: I041113
• CAS Number: 2134641-34-0
• Purity: ≥95%

Epcoritamab（Cat No.:I041113）is a bispecific antibody under investigation for the treatment of hematologic cancers, particularly B-cell malignancies such as non-Hodgkin lymphoma. It targets two antigens: CD3 on T cells and CD20 on B cells. By binding to both, Epcoritamab activates T cells to selectively target and kill CD20-positive B cells, including malignant ones. This novel approach enhances immune-mediated tumor destruction while minimizing damage to healthy tissues. Ongoing clinical trials are evaluating its safety, efficacy, and potential as a therapeutic option for patients with refractory or relapsed B-cell malignancies.